Ran Frenkel, Chief Development Operations Officer at Karyopharm Therapeutics Inc. (KPTI), sold 2,975 shares at $16.48 ($49K) on 2020-02-19, disclosed to the SEC on 2020-02-21.
Open-market sale of $49k KPTI by Chief Development Operations Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KPTI | SELL | 2022-02-09 | $20K | — | Filing → |
| KPTI | SELL | 2021-02-22 | $43K | — | Filing → |
| KPTI | SELL | 2021-02-17 | $32K | — | Filing → |